MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 30, 2004; DOI: 10.1124/mol.104.000893


0026-895X/04/6605-1236-1247$20.00
Mol Pharmacol 66:1236-1247, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.000893v1
66/5/1236    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dilmac, N.
Right arrow Articles by Hockerman, G. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dilmac, N.
Right arrow Articles by Hockerman, G. H.

Molecular Determinants of Frequency Dependence and Ca2+ Potentiation of Verapamil Block in the Pore Region of Cav1.2

Nejmi Dilmac, Nathan Hilliard, and Gregory H. Hockerman

Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences (N.H., G.H.H.) and Graduate Program in Biochemistry and Molecular Biology (N.D.), Purdue University, West Lafayette, Indiana

Verapamil block of Cav1.2 is frequency-dependent and potentiated by Ca2+. We examined the molecular determinants of these characteristics using mutations that effect Ca2+ interactions with Cav1.2. Mutant and wild-type Cav1.2 channels were transiently expressed in tsA 201 cells with {beta}1b and {alpha}2{delta} subunits. The four conserved glutamates that compose the Ca2+ selectivity filter in Cav1.2 were mutated to Gln (E363Q, E709Q, E1118Q, E1419Q) and the adjacent conserved threonine in each domain was mutated to Ala (T361A, T707A, T1116A, T1417A). The L-type-specific residues in the domain III pore region (F1117G) and the C-terminal tail (I1627A) were also mutated and assayed for block by verapamil using whole-cell voltage-clamp recordings in 10 mM Ba2+ or 10 mM Ca2+. In Ba2+, none of the pore-region mutations reduced the fraction of current blocked by 30 µM verapamil at 0.05 Hz stimulation. However, all of the pore-region mutations abolished Ca2+ potentiation of verapamil block at 0.05 Hz. The T1116A, F1117G, E1118Q, and E1419Q mutations all significantly reduced frequency-dependent verapamil block (1-Hz stimulation) in both Ba2+ and Ca2+. The I1627A mutation, which disrupts Ca2+-dependent inactivation, increased the fraction of closed channels blocked by 30 µM verapamil in Ba2+ but did not affect frequency-dependent block in Ba2+ or Ca2+. Our data suggest that the pore region of domain III may contribute to a high affinity verapamil binding site accessed during 1-Hz stimulation and that Ca2+ binding to multiple sites may be required for potentiation of verapamil block of closed channels.


Received March 29, 2004; accepted July 28, 2004

Address correspondence to: Gregory Hockerman, 575 Stadium Mall Dr., West Lafayette, IN 47907-2091. E-mail: gregh{at}pharmacy.purdue.edu




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
D. B. Tikhonov and B. S. Zhorov
Molecular Modeling of Benzothiazepine Binding in the L-type Calcium Channel
J. Biol. Chem., June 20, 2008; 283(25): 17594 - 17604.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Beyl, E. N. Timin, A. Hohaus, A. Stary, M. Kudrnac, R. H. Guy, and S. Hering
Probing the Architecture of an L-type Calcium Channel with a Charged Phenylalkylamine: EVIDENCE FOR A WIDELY OPEN PORE AND DRUG TRAPPING
J. Biol. Chem., February 9, 2007; 282(6): 3864 - 3870.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. S. Freeze, M. M. McNulty, and D. A. Hanck
State-Dependent Verapamil Block of the Cloned Human Cav3.1 T-Type Ca2+ Channel
Mol. Pharmacol., August 1, 2006; 70(2): 718 - 726.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics